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Inﬂammatory mediatorsTrypanosoma cruzi, the etiological agent of Chagas' disease, induces a persistent inﬂammatory response. Macro-
phages are a ﬁrst line cell phenotype involved in the clearance of infection. Upon parasite uptake, these cells in-
crease inﬂammatory mediators like NO, TNF-α, IL-1β and IL-6, leading to parasite killing. Although desired,
inﬂammatory response perpetuation and exacerbation may lead to tissue damage. Peroxisome proliferator-
activated receptors (PPARs) are ligand-dependent nuclear transcription factors that, besides regulating lipid
and carbohydrate metabolism, have a signiﬁcant anti-inﬂammatory effect. This is mediated through the interac-
tion of the receptors with their ligands. PPARγ, one of the PPAR isoforms, has been implicated in macrophage
polarization fromM1, the classically activated phenotype, to M2, the alternatively activated phenotype, in differ-
ent models of metabolic disorders and infection. In this study, we show for the ﬁrst time that, besides PPARγ,
PPARα is also involved in the in vitro polarization of macrophages isolated from T. cruzi-infected mice. Polariza-
tion was evidenced by a decrease in the expression of NOS2 and proinﬂammatory cytokines and the increase in
M2markers like Arginase I, Ym1,mannose receptor and TGF-β. Besides, macrophage phagocytic activitywas sig-
niﬁcantly enhanced, leading to increased parasite load. We suggest that modulation of the inﬂammatory
response by both PPARs might be due, at least in part, to a change in the proﬁle of inﬂammatory macrophages.
The potential use of PPAR agonists as modulators of overt inﬂammatory response during the course of Chagas'
disease deserves further investigation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Trypanosoma cruzi (T. cruzi), an obligate intracellular protozoan par-
asite, is the etiological agent of human American trypanosomiasis, a de-
bilitating disease widely distributed throughout Central and South
America. Upon infection, the parasite has the ability to invade andmul-
tiply within diverse cell types, including macrophages. The acute phase
of infection is characterized by the presence of parasites in the host
bloodstream and diverse tissues. However, the heart is one of the
main targets of this disease, causing serious cardiac alterations in the
acute and chronic phases. A crucial step in cardiomyopathy is the inﬁl-
tration of monocytes and their differentiation into macrophages.
These cells may either inhibit T. cruzimultiplication or provide a favor-
able environment in which it can divide and be disseminated to other
sites within the body [1].uay 2155, piso 12, Buenos Aires
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ed.uba.ar (N.B. Goren).Macrophages are a heterogeneous cell population that adapts and
responds to a large variety of microenvironmental signals. They play
essential roles in immunity and lipid homeostasis and, as professional
scavengers, they phagocytize microbes and apoptotic and necrotic
cells. Although macrophages play important roles in injury responses
and tissue remodeling, it is generally considered that sustained activa-
tion of these responses may precipitate pathological states. Moreover,
the activation state and functions ofmacrophages are profoundly affect-
ed by different cytokines and microbial products [2]. The immune phe-
notype of macrophages depends on various factors, including the
cellular environment and the presence of various activator molecules
[3]. In addition to pathogen clearance, they also regulate the resolution
of inﬂammatory responses. These opposing or polarized activities are
initiated and maintained by immunomodulatory factors such as cyto-
kines and microbial products and manifest in distinct activation states.
While Th1 cytokines, such as interferon γ (IFNγ), interleukin (IL)-1β,
and lipopolysaccharide (LPS), induce a “classical” activation proﬁle
(M1), Th2 cytokines, such as IL-4 and IL-13, induce an “alternative”
activation program (M2) in macrophages. Moreover, macrophages are
considered plastic cells because they can switch from an activated M1
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tious or inﬂammatory diseases, such as chronic Chagas cardiomyopathy,
may be caused not only by a sustained proinﬂammatory reaction but
also by the failure of anti-inﬂammatory control mechanisms.
Peroxisome proliferator-activated receptor (PPAR)γ is a member of
the nuclear hormone receptor family that has been implicated in medi-
atingmanymetabolic, endocrine and cardiovascular disorders aswell as
inﬂammation [6]. Its natural ligand, 15-Deoxy-Δ12,14 prostaglandin J2
(15dPGJ2), has high afﬁnity for PPARγ. Several reports have shown
that 15dPGJ2 can repress some genes in activated macrophages and
cardiomyocytes, including the genes for inducible nitric oxide synthase
(NOS2), cyclooxygenase 2 (COX2) and tumor necrosis factor (TNF-α),
and that this repression is partially dependent on PPARγ expression [7,
8]. 15dPGJ2 is normally present in vivo during the resolution phase of in-
ﬂammation, suggesting that it may function as a feedback regulator of
the inﬂammatory response [9].
PPARα was identiﬁed in the early 1990s as a target of hypolipid-
emic ﬁbrate drugs and other compounds that induce peroxisome
proliferation in rodents [10]. PPARα is expressed in cells that have
active fatty acid oxidation like hepatocytes, cardiomyocytes,
enterocytes, smooth muscle cells, and kidney cells and has been im-
plicated in the regulation of cellular energetic processes. PPARα li-
gands, such as ﬁbrates, decrease triglyceride levels and reduce the
incidence of cardiovascular events and atherosclerosis [11]. PPARα
is expressed in human and mouse immune cells, including lympho-
cytes, macrophages, and dendritic cells, and numerous studies have
implicated PPARα in the negative regulation of inﬂammatory re-
sponses. Different investigations using PPARα ligands have shown
a reduction in the symptoms of inﬂammation and disease in several
models, including allergic airway disease, arthritis, and inﬂammato-
ry bowel disease [12].
In particular, PPARα ligands can inhibit the expression of various pro-
inﬂammatory genes, such as IL-6, vascular cell adhesion molecule 1,
platelet-activating factor receptor and COX2, in response to cytokine ac-
tivation [13,14].
Macrophages neither appropriately suppress inﬂammatory cyto-
kine production nor acquire an oxidative metabolic program associ-
ated with the M2 phenotype in the absence of PPARα signaling.
The importance of PPARγ in regulating the M1/M2 phenotypic
switch has been conﬁrmed by Amine Bouhlel et al., who demonstrated
that activation of PPARγ potentiates the polarization of circulating
monocytes tomacrophages of theM2phenotype [15]. Subsequent stud-
ies reported that an active PPARγ pathway is a prominent feature of
alternatively activated (M2) macrophages and that M2-type responses
are compromised in the absence of PPARγ expression [16]. PPARγ
expression is important for the full expression of certain genes charac-
teristic of M2 macrophages, especially the gene encoding Arginase I,
a direct PPAR target [16,17]. PPARα may be involved together with
PPARγ in the suppression of proinﬂammatory cytokines. Indeed, several
studies also suggest an anti-inﬂammatory role for PPARα, which inter-
feres with the NF-κB and AP-1 inﬂammatory pathways [18].
In the present study, we evaluated the effects of 15dPGJ2 (a natural
PPARγ ligand) andWY14643 (a synthetic PPARα ligand) on themodu-
lation of the inﬂammatory response and on the phenotypic changes of
peritoneal macrophages from T. cruzi-infected mice. Also, we deter-
mined whether their polarization could modify their phagocytic func-
tions or parasitic load.
2. Material and methods
2.1. Mice and infection
BALB/c male mice (8–10 per group) were infected intraperitone-
ally with 1 × 105 bloodstream trypomastigotes of a lethal RA (pan-
tropic/reticulotropic) subpopulation of T. cruzi [19] and were
sacriﬁced at 1, 2 and 6 days post infection (p.i.), depending on theexperimental protocol. A 12-hour day/night cycle and water and
food ad libitum with a standard diet were provided. Euthanasia was
carried out by CO2 inhalation. Mice used in this study were bred and
maintained in the animal facility of the Department of Microbiology,
Parasitology and Immunology, School ofMedicine, University of Buenos
Aires in accordance with the guidelines of the NIH (Guide for the Care
and Use of Laboratory Animals, 1996). Protocols for animal mainte-
nance and use were approved by the Institutional Committee for the
Care and Use of Laboratory Animals (CICUAL), School of Medicine, Uni-
versity of Buenos Aires.
2.2. Puriﬁcation of peritoneal macrophages
Macrophages were obtained by washing the peritoneal cavity of
BALB/c mice with 8 ml of RPMI-1640 culture medium (Invitrogen
Life Technologies, Grand Island, NY), supplemented with 10% of
heat-inactivated fetal bovine serum (FBS) (Internegocios S.A.,
Argentina) and antibiotics (50 μg/ml of penicillin, streptomycin
and gentamicin) [20]. Cells were left to adhere to the plastic surface
of cell culture dishes, 35 × 10mm (Greiner Bio One International AG)
for 3 h at 37 °C under 5% CO2 atmosphere.
2.3. In vitro treatment of macrophages with PPAR agonists
Cultured macrophages were treated with 2 μM 15dPGJ2, a PPARγ
natural ligand (Sigma-Aldrich Co., St. Louis, USA) or 100 μM
WY14643, a synthetic PPARα ligand (Sigma-Aldrich Co., St. Louis,
USA) 3 h after cell plating. Stock 15dPGJ2 (molarity) and WY14643
(molarity) solutionswere prepared in ethanol and in DMSO, respective-
ly. Thereafter, stock solutions were diluted in culture medium to ﬁnal
concentrations. Treatments were performed 30 min prior to infection,
when required [21]. After the different treatments cell viability was ex-
amined by a Trypan blue dye exclusion test.
2.4. FACS analysis of peritoneal exudate cells (PEC)
PEC obtained from T. cruzi-infected (6 dpi) and age-matched un-
infected (control) mice were plated onto 24-well polystyrene plates
and detached after 24 h of incubation at 37 °C under 5% CO2. De-
tached cells were incubated withmAb 2.4G2 (anti-FcγR) and stained
during 30 min on ice with a rat monoclonal antibody (IgG2b) to
mouse F4/80, labeled with allophycocyanin (APC, AbD Serotec, Bio-
Rad, USA) diluted 1:100 in FACS buffer (1× PBS containing 1% BSA
and 0.1% sodium azide). Non-speciﬁc binding was controlled using
an APC-labeled isotype-matched irrelevant antibody. For macro-
phage proﬁling, cells were ﬁxed with 4% paraformaldehyde, washed
with Perm-Wash™ (Becton Dickinson, USA), incubated with rabbit
polyclonal antibodies to NOS2 or Arginase I at the appropriate dilu-
tion, and stained with FITC-labeled goat anti-rabbit IgG diluted in
Perm-Wash™, washed twice with the same solution and resuspend-
ed in 1× PBS. At least ten thousand events were acquired using a
FACSCanto ﬂow cytometer (Becton-Dickinson, USA). The percentage
of positive cells and mean ﬂuorescence intensity (MFI) were deter-
mined using the Weasel ﬂow cytometry software (Walter and Elisa
Hall Institute, Melbourne, Australia).
2.5. NO measurement
To determine the amount of NO released into the medium, nitrate
was reduced to nitrite and this was measured spectrophotometrically
by the Griess reaction, as previously described [22]. The absorbance at
540 nmwas compared with a standard curve of NaNO2. In situ NO syn-
thesis was performed in peritoneal macrophages loaded with 4-amino-
5-methylamino-2′,7′-diﬂuoroﬂuorescein diacetate (DAF-FM), follow-
ing the controls and recommendations of the supplier (Molecular
Probes, Eugene, OR, USA). DAF-DM is a non-ﬂuorescent compound
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emission at 495/515 nm [23].
2.6. Quantitative real-time reverse transcriptase-polymerase chain reaction
(Q-RT-PCR)
Total RNAwas extracted from frozen cells using a Trizol reagent (Life
Technologies, Inc.). Total RNA was reverse transcribed using Expand
Reverse Transcriptase (Invitrogen Corp.). Q-RT-PCR was performed
using a 5× HOT FIREPol® EvaGreen® qPCR Mix Plus (ROX) (Solis
BioDyne Corp.) in anApplied Biosystems 7500 sequence detector. Prim-
er sequences were: TNF-α forward: 5′-ATGAGCACAGAAAGCATGATC-
3′, reverse: 5′-TACAGGCTTGTCACTCGAATT-3′; IL-1β forward: 5′ TTGA
CAGTGATGAGAATGACC-3′, reverse: 5′-CAAAGATGAAGGAAAAGA
AGG-3′; IL-6 forward: 5′-TGATGCACTTGCAGAAAACAA-3′, reverse: 5′-
GGTCTTGGTCCTTAGCCACTC-3′; PPARα forward: 5′-GCTGGTGTACGA
CAAGTG-3′, reverse: 5′-GTGTGACATCCCGACAGAC-3′; PPARγ forward:
5′-ATCTACACGATGCTGGC-3′, reverse: 5′-GGATGTCCTCGATGGG-3′;
NOS2 forward: 5′-CACAGCAATATAGGCTCATCCA-3′, reverse: 5′-GGAT
TTCAGCCTCATGGTAAAC-3′; Ym1 forward: 5′-GGATGGCTACACTGGA
GAAA-3′, reverse: 5′-AGAAGGGTCACTCAGGATAA-3′; mannose recep-
tor (MR) forward: 5′-CAAGGAAGGTTGGCATTTGT-3′, reverse: 5′-CCTT
TCAGTCCTTTGCAAGC-3′; and TGF-β forward: 5′-CACCGGAGAGCCCT
GGATA-3′, reverse: TGTACAGCTGCCGCACACA-3′. All samples were an-
alyzed in the same run for 18S expression for normalization: forward:
5′ AACACGGGAAACCTCACCC-3′ and reverse: 5′-CCACCAACTAAGAACG
GCCA-3′. PCR parameters were 52 °C for 2 min, 95 °C for 15 min, and
40 cycles of 95 °C for 30 s, 63 °C (for TGF-β) or 60 °C (for NOS2, IL-6,
MR, TNF-α and 18S) or 56 °C (for Ym1, IL-1β and PPARα) or 54 °C
(for PPARγ) for 1 min. Quantiﬁcation was calculated using the compar-
ative threshold cycle (Ct) method and efﬁciency of the RT reaction (rel-
ative quantity, 2−ΔΔCt). The replicates were then averaged and fold
induction was determined, considering the value at time zero as 1 [23].
2.7. Determination of cytokine levels
TNF-α, IL-1β and IL-6 were quantiﬁed in culture supernatants by
enzyme-linked immunosorbent assays (ELISA) using DuoSet antibody
pairs (R&D Systems, Minneapolis, MN).
2.8. Small interfering RNA (siRNA)
Macrophages were cultured up to 30–50% conﬂuence in RPMI
medium containing 5% FBS without antibiotics for 24 h. Thereafter,
cells were transfected with PPARα or PPARγ siRNA that targets
PPARα and PPARγ mRNA, respectively, following the manufacturer's
instructions (Santa Cruz Biotechnology Inc., CA, USA). Transfections
were performed with Oligofectamine (Life Technologies, Inc., CA, USA)
as speciﬁed by the manufacturer. Assays for gene activity were
performed at 24 and 72 h post transfection. The impact of PPARα-
siRNA and PPARγ-siRNA interference on different mRNA (Section 2.6)
was evaluated by Q-RT-PCR. For the assessment of the effect of RNA
silencing, infections were carried out at a ratio of 5:1 parasites to a cell
[23].
2.9. Preparation of cytosolic, nuclear and total protein extracts for Western
blot
Cultured cells were washed with PBS and scraped off the dishes
with 100 ml of buffer A (10 mmol/l HEPES; pH 7.9, 1 mmol/l EDTA,
1 mmol/l EGTA, 10 mmol/l KCl, 1 mmol/l DTT, 0.5 mmol/l
phenylmethyl sulfonyl ﬂuoride, 40 mg/ml leupeptin, 2 mg/ml
tosyllysylchloromethane, 5 mmol/l NaF, 1 mmol/l NaVO4, 10 mmol/
l Na2MoO4) and NP-40 was added to reach 0.5% (vol/vol). After
15 min at 4 °C, the tubes were gently vortexed for 10 s, and cytosolic
extracts were collected by centrifugation at 13,000 g for 30 s. Thesupernatants were stored at −20 °C (cytosolic extracts). Nuclear
proteins were obtained by centrifugation at 13,000 g for 5 min, and
aliquots of the supernatant (nuclear extracts) were stored at−80 °C.
Total protein extracts were obtained after washing with PBS and
then lysed adding OGP (Sigma-Aldrich Co., St. Louis, USA) lysis buffer
(90ml/dish). Then, the disheswere kept on ice for 30minwith swirling
and the scrapped cells were centrifuged at 7000 g at 4 °C for 10min. The
supernatant was transferred to a clean tube and stored at −20 °C.
Protein concentration was determined by the Bradford method using
a Bio-Rad Protein Assay (BIO-RAD CA., USA) reagent and bovine
serumalbumin (BSA) (Sigma-Aldrich Co., St. Louis, USA) as pattern pro-
tein [22]. For Western blot analysis, total proteins were boiled in
Laemmli sample buffer, and equal amounts of protein (40–50 mg)
were separated by 10–12% SDS-PAGE. The gels were blotted onto a
Hybond-P membrane (GE Healthcare, Madrid, Spain) and incubated
with the following antibodies (Abs): anti-NOS2, anti-Arginase I and
anti-α-actin (Santa Cruz Biotechnology, CA, USA). The blots were
revealed by enhanced chemiluminescence (ECL) in an Image Quant
300 cabinet (GE Healthcare Biosciences, PA, USA) following the
manufacturer's instructions. Band intensity was analyzed using an
NIH-ImageJ program [8].
2.10. Immunoﬂuorescence and digital image analysis
Parasite staining and digital imaging were performed as previously
described by Hovsepian et al., with minor modiﬁcations [23]. Brieﬂy,
macrophage cells grown on round glass coverslips were blocked with
3% normal goat serum in PBS. The percentage of infected cells and the
number of amastigotes per cell were determined by analyzing the pres-
ence of intracellular amastigotes by immunoﬂuorescence. For this pur-
pose, a rabbit polyclonal IgG directed to T. cruzi and a FITC-labeled goat
anti-rabbit IgG (Sigma-Aldrich Co., St. Louis, USA) were used at 1:200
dilutions (determined by titration). Macrophage cell nuclei were
stained with DAPI (300 nM in PBS). At least 30 random microscopic
ﬁelds (400×) and 1000 cells per culture were acquired using a Spot
RT digital camera attached to an Eclipse 600 ﬂuorescence microscope
(Nikon Inc., USA). Cell quantiﬁcation was performed with the ImageJ
open source software developed at the NIH, USA.
2.11. Phagocytic assay
Macrophages were infected with T. cruzi and cultured at 37 °C and
5% CO2 for 48 h. Then, the cultures were challenged with 50 FITC-
labeled E. coli per cell. Phagocytosis was stopped after 60 min by wash-
ing the macrophages with ice-cold PBS. Afterwards, macrophages were
incubatedwith 1% antibiotic (streptomycin and penicillin) for 30min to
eliminate microorganisms that were not phagocyted. The number of
E. coli engulfed by macrophages was determined by FACS. The distinc-
tion between internalized bacteria cells and bacteria attached to the
cell surface was done by quenching of extracellular FITC ﬂuorescence
with trypan blue [24]. The remaining ﬂuorescence was quantiﬁed on a
Partec PAS III ﬂow cytometer, and the datawere analyzedwithWinMDI
software. The uptake index was calculated multiplying the percentage
of FITC-positive cells by the mean ﬂuorescence intensity. Uninfected
animals were used as controls.
2.12. Statistical analysis
Results are expressed as the mean ± SD of at least three separate
experiments. P values were determined using Student's t-test. Differ-
ences were considered statistically signiﬁcantwhen P b 0.05. The differ-
ences between the different test groups for the percentages of infected
cells and for the number of amastigotes per cell were determined using
one-way ANOVA and the Tukey post-test at a signiﬁcance level of α=
0.05. NO levels using DAF-FM and ﬂuorescence microscopy were quan-
tiﬁed by integrating the area under the curve (AUC) ﬂuorescence (or
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that pixel density is directly proportional to NO production. The differ-
ences were established for a signiﬁcance level of α= 0.05 by one-way
ANOVA and Bonferroni post-test for multiple comparisons. Statistical
analyses were performed using the GraphPad Prism 4.0 program.
3. Results
3.1. Macrophage activation in a mouse model of T. cruzi infection
Since peritoneal exudate cells are heterogeneous in composition we
sought to determine the proportion of macrophages in our prepara-
tions. Flow cytometry analysis demonstrated that more than 75% ofFig. 1. Characterization of plastic-adherent peritoneal exudate cells (PECs) from T. cruzi infected
anti-F4/80 monoclonal antibody coupled to APC was used to determine the proportion of macr
netics of NOS2 expression was determined by Western blot with a speciﬁc antibody. Protein l
Griess reaction in the supernatants (C). Results show a representative experiment out of threethe adherent cells expressed the macrophage-speciﬁc F4/80 marker
(Fig. 1A). To determine whether peritoneal macrophages were activat-
ed after T. cruzi infection, NOS2 expression and nitric oxide (NO) pro-
duction were analyzed as two of the main modulators of
inﬂammation. Expression of NOS2 and production of NO in the primary
culture of macrophages were assessed at 1, 2 and 6 dpi. Both were de-
tected only at 6 dpi. At this time there was a signiﬁcant expression of
NOS2 (P b 0.01) (Fig. 1B) and release of NO (51.5 ± 4 μM vs. 5.5 ±
1 μM; infected vs. uninfected cells; P b 0.01) (Fig. 1C). Since NOS2 ap-
peared at 6 dpi, we tested Arginase I expression at this time point.
Fig. 1D shows a higher expression in infected mice than in controls. To
determine the proﬁle of macrophages upon T. cruzi infection, the ex-
pression of NOS2 and Arginase I was assessed by FACS on mouse PEC.mice. PECs were obtained from T. cruzi-infected and control mice. FACS analysis using an
ophages in the plastic-adherent cell fraction. A representative histogram is shown (A). Ki-
evels were normalized against α-actin (B). Kinetics of NO production was quantiﬁed by a
performed. ** P b 0.01 vs. uninfected cells.
Fig. 2. Proinﬂammatory cytokine production bymacrophages from T. cruzi-infectedmice. Peritonealmacrophageswere obtained from BALB/cmice infectedwith T. cruzi, at 1, 2 and 6 days
post infection (dpi). Q-RT-PCRassayswere performed and TNF-α (A), IL-1β (C) and IL-6 (E)mRNAexpressionwas analyzed. The resultswere normalized against 18S rRNA. Results show a
representative experiment out of three performed. ** P b 0.01 vs. uninfected cells. Quantitation of cytokine release to the culturemediumwas performed by capture ELISA. Bar graphs show
the secretion of TNF-α (B), IL-1β (D) and IL-6 (F) by macrophages from T. cruzi-infected (ﬁlled bars) and control (hollow bars) mice. *** P b 0.0001 vs. uninfected cells.
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was higher than 1, suggesting that infection drives macrophages to-
wards an M1 proinﬂammatory proﬁle. To further conﬁrm this, mRNA
levels of proinﬂammatory cytokines were assessed by Q-RT-PCR. Fig. 2
shows that transcription of proinﬂammatory cytokine mRNA was sig-
niﬁcantly higher in macrophages from infected mice than in controls,
as early as 24 h after infection. Fold induction for the different cytokines
were: TNF-α (91 ± 9.1 vs. 1 ± 0.2, T. cruzi vs. uninfected, P b 0.01,
Fig. 2A), IL-1β (88.3 ± 10 vs. 1 ± 0.3, T. cruzi vs. uninfected, P b 0.01,
Fig. 2C) and IL-6 (174 ± 15 vs. 1 ± 0.2, T. cruzi vs. uninfected, P b 0.01,
Fig. 2E) indicating that these macrophages are classically activated. Cy-
tokine secretion by macrophages, 48 h after mouse infection, was mea-
sured by ELISA in culture supernatants. As shown in Fig. 2B, D and F,
secretion of TNF-α, IL-1β and IL-6, respectively, was signiﬁcantly higher
in macrophages from T. cruzi-infected mice than in controls.3.2. Macrophage M2 polarization induced by PPAR ligands
Although PPARγ ligands regulate the expression of MR, CD36 and
other markers of alternative activation of macrophages [25–27], this
phenomenon has not been addressed under conditions of T. cruzi infec-
tion. Therefore, the next stepwas to evaluate PPARγ and PPARα expres-
sion in macrophages from infected mice. The mRNA levels of these
PPARs were signiﬁcantly increased in macrophages from infected mice
(P b 0.01 vs. uninfected; Fig. 3A), conﬁrming up-regulation of these re-
ceptors under this pathological condition. No signiﬁcant differences
were found in the expression of PPARγ or PPARα when macrophages
were treated either with 15dPGJ2 (2 μM) or WY14643 (100 μM), re-
spectively (Fig. 3A). To determine the effects of PPAR ligands on the po-
larization of peritonealmacrophages, the expression of M2macrophage
activation markers was assessed by western blot and Q-RT-PCR. When
Fig. 3.MacrophageM2 polarization induced by PPAR ligands. Peritoneal macrophages were obtained from infectedmice at 6 dpi and treatedwith 15dPGJ2 (2 μM) orWY14643 (100 μM).
PPARγ and PPARαmRNA expressionwas analyzed byQ-RT-PCR. The resultswere normalized against 18S rRNA (A). Arginase I expressionwas determined byWestern blot with a speciﬁc
antibody. Protein levelswere normalized againstα-actin (B).MR, Ym1 and TGF-βmRNA expressionwas analyzed byQ-RT-PCR. The results were normalized against 18S rRNA (C). Results
show a representative experiment out of three performed. * P b 0.05 vs. uninfected cells. ** P b 0.01 vs. uninfected cells. # P b 0.05 vs. untreated infected cells.
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(2 μM), Arginase I protein expression increased 68.17 ± 11.6% vs. un-
treated infected cells, whereas when they were treated with the
PPARα ligand WY14643 (100 μM), Arginase I protein expression in-
creased 65.9± 9.8% vs. untreated infected cells (P b 0.05; Fig. 3B). In ad-
dition,MR expression increased 91.66± 12.9% in infectedmacrophages
vs. control cells, and the treatment with 15dPGJ2 or WY14643 further
increased the mRNA levels of this M2 marker (145.83 ± 17.6%;
185.83 ± 22.8%, respectively) vs. untreated infected cells (P b 0.05)
(Fig. 3C). The same behavior was observed when Ym1 and TGF-β
were analyzed as markers of M2 macrophages: Ym1 increased
96.99 ± 17.4% in infected cells and 15dPGJ2 and WY14643 further in-
creased their mRNA levels (164.56 ± 13.6% and 231.53 ± 18.31%, re-
spectively) vs. untreated infected cells (P b 0.05). The same behavior
was also determined for TGF-β, which increased 64.28 ± 10.71% in in-
fected cells in comparison to uninfected cells (P b 0.05) and 15dPGJ2
and WY14643 additionally increased their levels (260.71 ± 13.6% and
242.85 ± 14.24% respectively) vs. untreated infected cells (P b 0.05)
(Fig. 3C). We further addressed the role of PPAR agonists with regard
to macrophage polarization at the single cell level, using FACS. For this
purpose, intracellular expression of NOS2 and Arginase I was deter-
mined on PPAR ligand-treated T. cruzi-infected and uninfected control
PEC. In vitro treatmentwith PPAR agonists signiﬁcantly decrease the ex-
pression of NOS2 by macrophages obtained from infected mice in com-
parison with untreated macrophages obtained from the same source(Fig. 4A). The same treatment signiﬁcantly increases the expression of
Arginase I, as shown in Fig. 4B. The NOS2/Arginase I MFI ratio signiﬁ-
cantly increased upon T. cruzi infection (16.3 vs. 0.21, infected vs. unin-
fected control), suggesting a bias towards theM1 proﬁle. Moreover, the
MFI ratios of in vitro PPAR ligand-treatedmacrophageswere signiﬁcant-
ly reduced (16.3 vs. 3.19, infected vs. infected and 15dPGJ2-treated; 16.3
vs. 2.43, infected vs. infected andWY14643-treated, Fig. 4C). Treatment
of PEC from uninfectedmice with PPAR agonists did not induce a signif-
icant change in the expression of Arginase I or NOS2 (data not shown).
3.3. 15dPGJ2 and WY14643 inhibit NOS2, NO and pro-inﬂammatory
cytokines
To determine whether PPARγ and PPARαmodulate inﬂammatory
mediators, infected macrophages were treated with 15dPGJ2 and
WY14643, and NOS2, NO and cytokines were evaluated. Western blot
assays and Q-RT-PCR also revealed that PPAR ligands are able to inhibit
mRNA andNOS2 protein expression in T. cruzi-infected cells (P b 0.05 vs.
untreated infected cells; Fig. 5A and B). In addition, we evaluated NO
release by the Griess method in macrophage culture supernatants
(T. cruzi: 53.1 ± 3.5 μM vs. uninfected: 5.2 ± 1 μM (P b 0.01);
T. cruzi + 15dPGJ2: 28.9 ± 6.3 μM and T. cruzi + WY14643: 22.4 ±
5.4 μM vs. untreated infected cells (P b 0.05); Fig. 5C). These results
are in agreement with in situ synthesis of NO by using 4-amino-
5methylamino-29,79-diﬂuoro-ﬂuorescein (DAF-FM), a highly sensitive
Fig. 4.Expression of NOS2 andArginase I at the single cell level in PPAR ligand-treated PEC. Cells from T. cruzi-infected and uninfectedmicewere treated in vitrowith 15dPGJ2 orWY14643.
Afterwards, cells were stained for FACS according toMaterial andMethods. Representative histograms show the number of events and expression level of NOS2 (A) and Arginase I (B). Bar
graph shows theMFI ratio of NOS2/Arginase I expression under different treatment conditions. Filled bar: PEC from infectedmice, light gray: 15dPGJ2-treated PEC from infectedmice, dark
gray: WY14643-treated PEC from infected mice, hollow bar: PEC from uninfected mice (C).
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until it reacts with NO, forming the ﬂuorescent benzotriazole. After
6 days post-infection with T. cruzi, macrophages showed intense ﬂuo-
rescence, whereas those treated with 15dPGJ2 or WY14643 showed
no ﬂuorescence (Fig. 5D), indicating a clear inhibition of NO production.
To assess the involvement of PPAR in these effects, PPARα and PPARγ
were silenced by the corresponding siRNA, and NOS2 expression evalu-
ated. Fig. 6 shows that when PPARαwas silenced,WY14643was unable
to exert its modulator effects on NOS2 expression while 15dPGJ2 was
partially able to inhibit NOS2 expression, suggesting that PPAR-
independent pathways could also participate in this event. Thus, we
asked whether 15dPGJ2 effects were also exerted by NF-κB, since we
have previously demonstrated that thiswas the case for cultured prima-
ry cardiomyocytes [21]. Fig. 7 shows that the Iκ-Bα inhibitor decreased
in cytosolic extracts after 30 min of infection, suggesting activation of
NF-κB. Furthermore, 15dPGJ2 and WY14643 treatment inhibited Iκ Bα
degradation, suggesting that PPAR ligands exert anti-inﬂammatory reg-
ulation through the NF-κB pathway.
When macrophages were incubated with 15dPGJ2 (2 μM) and
WY14643 (100 μM), we observed a signiﬁcant decrease in the mRNA
expression levels of proinﬂammatory cytokines by Q-RT-PCR, after
24 h of infection. When TNF-α fold gene expression was evaluated,
we found that T. cruzi increased 91 ± 9.1 vs. 1 ± 0.32 of the control
(P b 0.01) and that the treatment with PPAR ligands inhibited TNF-αexpression: T. cruzi + 15dPGJ2: 40.1 ± 12 and T. cruzi + WY14643:
30 ± 6.8 vs. T. cruzi-infected and untreated macrophages, all with
P b 0.01 (Fig. 8A). IL-1β determination showed the following fold chang-
es of gene expression: T. cruzi infection: 88.3±10 vs. 1±0.17 of the un-
infected; T. cruzi + 15dPGJ2: 19.8 ± 3.5; and T. cruzi + WY14643:
31.3 ± 5.1 (P b 0.01) (Fig. 8C). For IL-6, we found 174 ± 15 fold of
gene expression in T. cruzi-infected vs. 1 ± 0.24 of the uninfected and
T. cruzi + 15dPGJ2 90 ± 10.3 or 90.3 ± 11 fold for T. cruzi +
WY14643 (P b 0.01) (Fig. 8E). Cytokine secretion to the culture superna-
tant was assessed by ELISA in macrophages obtained from T. cruzi-
infected (2 dpi) and uninfected age-matched control mice. PPARγ and
PPARα agonists signiﬁcantly reduced the secretion of TNF-α (Fig. 8B),
IL-1β (Fig. 8D) and IL-6 (Fig. 8F) to the culture supernatants in compar-
isonwith untreated cells from infectedmice. PPAR agonists didn't show
a signiﬁcant effect on the basal secretion of proinﬂammatory cytokines
by macrophages from uninfected mice (data not shown).
3.4. PPAR activation enhances phagocytic activity of macrophages
To assess the phagocytic activity of infected macrophages, we per-
formed ﬂow cytometry assays to evaluate the internalization of E. coli
coupled to FITC. We observed that T. cruzi infection increased E. coli in-
ternalizationwith an uptake index of 1 × 103± 120 in comparisonwith
1.9 × 102 ± 23 of the uninfected cells with P b 0.05 (Fig. 9A). E. coli
Fig. 5. 15dPGJ2 andWY14643 inhibit NOS2 expression and NO release. Peritoneal macrophages were obtained from infectedmice at 6 dpi and treatedwith 15dPGJ2 (2 μM) orWY14643
(100 μM). NOS2 mRNA expression were analyzed by Q-RT-PCR. The results were normalized against 18S rRNA (A). NOS2 expression was determined byWestern blot with a speciﬁc an-
tibody. Protein levels were normalized against α-actin (B). NO levels were quantiﬁed by a Griess reaction in the supernatants (C). In situ synthesis of NO was evaluated by using the NO
ﬂuorescent probe DAF-FM and visualized by ﬂuorescence microscopy. Microphotographs (400×) are shown. The bar graph represents themean± SD of the integrated ﬂuorescence den-
sities (D). Results show a representative experiment out of three performed. ** P b 0.01 vs. uninfected cells. # P b 0.05 vs. untreated infected cells.
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with 15dPGJ2 andWY14643 increased the phagocytic activity of infect-
ed macrophages (T. cruzi + 15dPGJ2: 3.8 × 103 ± 250.3; T. cruzi +
WY14643: 5.8 × 103 ± 346.4 uptake index with P b 0.05, Fig. 9B).Fig. 6. PPARα and PPARγ are involved in the inhibitory effects of WY14643 or 15dPGJ2 in NOS
(100 μM) and infected with T. cruzi, or transfected with PPARα or PPARγ siRNA for 72 h, treate
was determined byWestern blot with a speciﬁc antibody. Protein levelswere normalized again
uninfected cells. ## P b 0.01 vs. untreated infected cells. ¥ P b 0.05 vs. infected + 15dPGJ2 treaThese effects were signiﬁcantly inhibited by PPARα and PPARγ silenc-
ing using siRNA, conﬁrming that infected macrophages display en-
hanced phagocytic capacity, an effect ampliﬁed by PPARα and PPARγ
activation (P b 0.05; Fig. 9B). Correspondingly, the parasite load of2 expression. Peritoneal macrophages were pretreated with 15dPGJ2 (2 μM) orWY14643
d with 15dPGJ2 (2 μM) or WY14643 (100 μM) and infected with T. cruzi. NOS2 expression
stα-actin. Results show a representative experiment out of three performed. ** P b 0.01 vs.
ted cells. § P b 0.05 vs. infected +WY14643 treated cells.
Fig. 7. Iκ-Bα expression inmacrophages infectedwith T. cruzi. Macrophages pretreated or notwith 15dPGJ2 (2 μM) orWY14643 (100 μM) and then infected for 30minwith T. cruzi. Iκ-Bα
expressionwas determined in cytosolic extracts byWestern blotwith a speciﬁc antibody. Protein levelswere normalized againstα-actin. Results show a representative experiment out of
three performed. * P b 0.05 vs. uninfected cells. # P b 0.05 vs. untreated infected cells.
Fig. 8. Regulation of inﬂammatory cytokine mRNA transcription and protein secretion to culture supernatants, by 15dPGJ2 or WY14643 in macrophages frommice infected with T. cruzi.
Peritonealmacrophageswere obtained from infectedmice at 1, 2 or 6 dpi and treatedwith 15dPGJ2 (2 μM)orWY14643 (100 μM). TNF-α (A), IL-1β (C) and IL-6 (E)mRNA expressionwas
analyzed by Q-RT-PCR. The results were normalized against 18S rRNA. Results show a representative experiment out of three performed. ** P b 0.01 vs. uninfected cells. ## P b 0.01 vs.
untreated infected cells. Quantitation of cytokine release to the culture medium was performed by capture ELISA. Bar graphs show the secretion of TNF-α (B), IL-1β (D) and IL-6 (F) of
T. cruzi-infected (black bars), T. cruzi-infected 15dPGJ2-treated (light gray) and T. cruzi-infected WY14643-treated (dark gray) plastic adherent PECs. *** P b 0.0001 vs. uninfected cells.
### P b 0.0001 vs. untreated infected cells.
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Fig. 9. Effect of 15dPGJ2 or WY14643 on the phagocytic activity and parasitism of macrophages infected with T. cruzi. Internalization of FITC-coupled E. coli by control (hollow bars) and
T. cruzi-infected (ﬁlled bars) peritoneal macrophages was assessed by ﬂow cytometry (A). Macrophages were pretreated with 15dPGJ2 (2 μM) or WY14643 (100 μM) and infected with
T. cruzi, or ﬁrst transfected with PPARα or PPARγ siRNA for 72 h, treated with 15dPGJ2 (2 μM) orWY14643 (100 μM) and then infected with T. cruzi. After 48 h, the cells were challenged
with 50 FITC-labeled E. coliper cell anduptakewas evaluated by FACS (B). Intracellular parasitismofmacrophageswas evaluated byﬂuorescencemicroscopyusing rabbit polyclonal serum
against to T. cruzi, followedby FITC-labeled goat anti-rabbit IgG. Afterwards, cellswere counterstainedwith DAPI (300 nM).Microphotographs are representative of 30ﬁelds taken at 400×
magniﬁcation.White arrows show intracellular parasites (C). The number of parasites/cell (right bar graph) are shown. * P b 0.05 vs. uninfected cells. # P b 0.05 vs. untreated infected cells.
¥ P b 0.05 vs. infected + 15dPGJ2 treated cells. § P b 0.05 vs. infected +WY14643 treated cells.
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was higher than in untreated T. cruzi-infected macrophages, as mea-
sured by ﬂuorescence microscopy using a rabbit T. cruzi-speciﬁc prima-
ry antiserum followed by FITC-anti-rabbit-IgG (P b 0.05; Fig. 9C).
4. Discussion
Previous studies have reported that PPARγ ligands are able to mod-
ify the macrophage proﬁle under different pathological conditions. In
this study, we report for the ﬁrst time that not only PPARγ, but also
PPARα changes M1 peritoneal macrophages from T. cruzi-infected
mice to express characteristic M2 markers. In addition, in vitro
15dPGJ2 and WY14643 treatment inhibits proinﬂammatory mediators
and enhances the phagocytic activity of infected macrophages.
Our study shows that T. cruzi infection stimulates M1-type macro-
phage activation, since we observed expression of NOS2 and the release
of high amounts of NO, plus increased mRNA transcription and secre-
tion of TNF-α, IL-6 and IL-1β in cultured peritoneal macrophages.
Accordingly, we have previously elucidated mechanistic aspects of the
onset of the inﬂammatory response in different models of T. cruzi infec-
tion and in macrophages stimulated with lipopolysaccharide (LPS),
where we demonstrated a signiﬁcant increase in NOS2 production as
well as in IL-6 and TNF-αmRNA expression in both cultured neonatal
cardiomyocytes and hearts of infected mice [8,21,28].This work focuses on the role of the natural PPARγ ligand and a syn-
thetic PPARα ligand on the modulation of the inﬂammatory response
and macrophage polarization in an in vitro experimental model of
T. cruzi infection. The results show that infection signiﬁcantly increases
the levels of PPARγ and PPARαmRNA expression bymacrophages com-
pared to uninfected cells. Consistent with this, PPARγ expression
increases in the spleen in a mouse model of visceral leishmaniasis
[29]. Noteworthy, elevation of PPARγ was observed by Nagajyothi
et al. in white adipose tissue (WAT), but not in brown adipose tissue
(BAT), in a murine model of Chagas' disease. Signiﬁcantly, the authors
found higher levels of chemokine and cytokine mRNA transcription in
BAT than inWAT. This suggests that PPARγ is involved in the downreg-
ulation of inﬂammation in this tissue [30].
Arginase I hydrolizes L-arginine into urea and ornithine, a precursor
of L-proline and polyamines, implicated in anti-inﬂammatory response
and tissue remodeling. Moreover, ornithine is a precursor in the path-
way leading to putrescine synthesis, which promotes parasite growth
[31–33]. Interestingly, Garrido et al. showed that cruzipain, the most
relevant T. cruzi serin-protease, increases the mannose receptor turn-
over leading to an increase in Arginase I activity that promotes
amastigote proliferation [33].
In the present work, we show that PPARγ and PPARα ligands inﬂu-
ence Arginase I expression in PPAR ligand-treated primary culture mac-
rophages derived from mice infected with T. cruzi. Interestingly, the
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WY14643, induced Arginase I expression concomitantly with NOS2 in-
hibition. Previous studies have shown that expression of both PPARγ
and Arginase I is induced by the Th2-derived cytokine IL-4 [34,35], pro-
viding a link between the two genes.
Gallardo-Soler et al. have described that PPARγ/δ drive macrophage
activation towards a Th2 phenotype in a model of Leishmania major
infection. These authors showed that PPARγ and PPARδ ligands induce
intracellular amastigote growth in macrophages and that this effect is
associated to increased Arginase I expression and activity, induced by
these PPARs [17]. In the same line of evidence, Li et al. showed, in a
model of lung cancer, that the synthetic PPARγ agonist pioglitazone
induces Arginase I expression, and that this effect was dependent on
the expression of PPARγ in the macrophages [36]. Since activation of
PPARγ in macrophages leads to transcriptional repression of inﬂamma-
tory genes, we determined characteristic markers of M1 andM2macro-
phage polarization. Isolated mouse peritoneal macrophages exhibit an
alternative M2 polarization upon the in vitro treatment with PPARγ
and PPARα ligands. Indeed, mRNA expression of Ym1, MR and TGF-β,
which are characteristic ofM2macrophage polarization [37], was great-
ly increased by 15dPGJ2 and WY14643 in the experimental model
described herein. It must be noted, however, that there are conﬂicting
results on the role of PPARα activation to drive macrophages towards
an M2 proﬁle. Bouhlel et al. showed that PPARα is not involved in
M1-to-M2 bias, using correlation analysis of Q-RT-PCR studies on
human monocyte-derived in vitro cultured macrophages [38]. On the
contrary, Lovren et al. showed, in the context of visceral obesity-
induced inﬂammation and cardiometabolic risk, that treatment of
human monocytes with adiponectin is involved in the M1-to-M2 bias,
through a priming effect dependent on PPARα, using the speciﬁc antag-
onist GW6471 [39].
We showed that peritonealmacrophages from T. cruzi-infectedmice
have anM1 phenotype characterized by production of high amounts of
NO and increased TNF-α, IL-6 and IL-1β mRNA expression. Treatment
with 15dPGJ2 and WY14643 inhibited these cytokines and NO produc-
tion and induced anti-inﬂammatory factors characteristic of anM2 phe-
notype. Our results also show that NF-κB is activated in macrophages
after infection and, upon 15dPGJ2 or WY14643 treatment Iκ-Bα degra-
dation is inhibited, suggesting that these PPAR ligands exert anti-
inﬂammatory regulation through PPAR-independent mechanisms
involving the NF-κB pathway. In previous studies, we observed that
15dPGJ2 exerts anti-inﬂammatory effects in LPS- or T. cruzi-stimulated
cardiac cells or in the heart of infected mice by means of PPARγ-
dependent and -independent mechanisms involving transcription fac-
tors like NF-κB [8,21,28]. In this regard, several authors have also
shown that both PPARγ and PPARα ligands may induce anti-
inﬂammatory responses through inhibition of NF-κB and independently
of their receptors [7,11,40]. Fernandez-Boyanapalli et al. demonstrated
that a deﬁciency in PPARγ expression leads to delayed engulfment of
apoptotic cells [41]. Also, Zhao et al. revealed that PPARγ agonist-
induced upregulation of CD36 in macrophages enhances the ability of
microglia to phagocytize red blood cells (in vitro assay) and suggested
that it might help to improve hematoma resolution [42]. In this work,
we showed that infection with T. cruzi increases the phagocytosis of
FITC-labeled E. coli bymacrophages in comparisonwith uninfected con-
trols. Moreover, we found that treatment with either 15dPGJ2 or
WY14643 further increases macrophage phagocytic activity. The roles
of PPARα and PPARγ in this effect were conﬁrmed by silencing these
receptors with siRNA.
Our data provide new insights into the role of PPARα and PPARγ
ligands inmacrophage polarization. Also, by using PPARα and PPARγ si-
lencing, we conﬁrm our previous ﬁndings on the involvement of PPAR-
independent pathways activated by PPAR ligands during T. cruzi
infection.
In summary, we demonstrated that treatment with PPARα and
PPARγ ligands drive macrophages towards an M2 proﬁle, markedlyinhibiting inﬂammatory mediators. Since PPAR signaling is involved in
switching macrophage polarity to a tissue-repairing phenotype that
might ameliorate inﬂammatory responses, we propose that treatment
with PPAR ligands as coadjuvants of the current anti-parasitic treat-
ments might be a new potential therapeutic approach, and may thus
open new avenues to the pharmacological resolution of inﬂammation
in Chagas' disease.
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